660-P: Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials

Achieving HbA1c targets, weight loss (WL) and systolic blood pressure (SBP) reductions lowers micro- and macrovascular risk in type 2 diabetes (T2D). In SUSTAIN clinical trials, once-weekly (OW) semaglutide, a glucagon-like peptide-1 analog, significantly reduced HbA1c and body weight (BW) and reduc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1)
Hauptverfasser: GÆDE, PETER, CATARIG, ANDREI-MIRCEA, DUNGAN, KATHLEEN M., HINDSBERGER, CHARLOTTE, ØLLGAARD, JENS, BAIN, STEPHEN C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Achieving HbA1c targets, weight loss (WL) and systolic blood pressure (SBP) reductions lowers micro- and macrovascular risk in type 2 diabetes (T2D). In SUSTAIN clinical trials, once-weekly (OW) semaglutide, a glucagon-like peptide-1 analog, significantly reduced HbA1c and body weight (BW) and reduced SBP (except in SUSTAIN 8) vs. comparators. This post hoc analysis evaluated composites of these endpoints with semaglutide vs. comparators in SUSTAIN 1-5 and 7-10. Trials were analyzed individually to determine the proportion of subjects achieving composite endpoints A (HbA1c
ISSN:0012-1797
1939-327X
DOI:10.2337/db21-660-P